Wiley buys Blackwell, creating a monster medical publisher

Share this article:
John Wiley & Sons is buying Blackwell Publishing in a marriage of two medical publishing giants. Hoboken-based Wiley will shell out £572 million (around $1.08 billion) for Blackwell, headquartered in Oxford, UK. Blackwell’s 2005 revenue was $380 million, about what Wiley’s scientific, technical and medical division generated. The combined business will publish approximately 1,250 scholarly peer-reviewed journals along with an extensive selection of books, Wiley said. Blackwell titles include The American Journal of Gastroenterology, Epilepsia, The American Journal of Transplantation and the Journal of the American Geriatrics Society. Wiley publishes Arthritis & Rheumatism, The Hospitalist, Hepatology and Annals of Neurology, among other titles.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...